- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Capecitabine, Computed Tomography, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Other + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 659
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 4,980
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epilepsy, Partial, Epilepsy, Localization Related
- Interventions
- Oxcarbazepine, Levetiracetam, Lamotrigine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 5 Years to 16 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • San Diego, California • Aurora, Colorado + 11 more
- Conditions
- Diabetes
- Interventions
- Blood Glucose meter
- Other
- Lead sponsor
- Ascensia Diabetes Care
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- San Diego, California • Tampa, Florida
- Conditions
- Plaque Psoriasis
- Interventions
- JNJ-77242113, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 684 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Fountain Valley, California + 42 more
- Conditions
- Phantom Limb
- Interventions
- Cognitive Behavioral Therapy and Mirror Retraining, Supportive therapy, Mirror retraining
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Long Beach, California • San Diego, California • San Francisco, California
- Conditions
- Breast Cancer
- Interventions
- Raloxifene, Tamoxifen
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 19,747 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 492
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 614
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 395 more
- Conditions
- Urolithiasis, Kidney Stone, Kidney Stones
- Interventions
- CVAC® SYSTEM, FLEXIBLE AND NAVIGATIONAL URETERAL ACCESS SHEATH (FANS) IN FLEXIBLE URETEROSCOPY (FURS)
- Device
- Lead sponsor
- Calyxo, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Hemophilia B
- Interventions
- CSL222 (AAV5-hFIXco-Padua)
- Genetic
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 4
- States / cities
- San Diego, California • Ann Arbor, Michigan • Pittsburgh, Pennsylvania + 1 more
- Conditions
- Narcolepsy
- Interventions
- Not listed
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 21 more
- Conditions
- Scalp Psoriasis
- Interventions
- LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 6
- States / cities
- San Diego, California • Jacksonville, Florida • Ormond Beach, Florida + 3 more
- Conditions
- Bone Metastases
- Interventions
- ExAblate 2000
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Parkinson's Disease Dementia (PDD)
- Interventions
- SYN120, Placebo
- Drug
- Lead sponsor
- Biotie Therapies Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Sun City, Arizona • La Jolla, California + 14 more
- Conditions
- Benign Prostatic Hypertrophy
- Interventions
- Cetrorelix Pamoate
- Drug
- Lead sponsor
- AEterna Zentaris
- Industry
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 56
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Laguna Hills, California + 49 more
- Conditions
- Healthy Human Volunteers
- Interventions
- Bolus, Basal
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Persian Gulf Syndrome
- Interventions
- Aerobic exercise, Cognitive behavioral therapy
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,064 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 18 more
- Conditions
- Food Insecurity
- Interventions
- Food Security Screening & Referral Program
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- La Jolla, California • San Diego, California
- Conditions
- Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
- Interventions
- LivIQ Leadless Pacemaker System
- Device
- Lead sponsor
- Biotronik, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 24
- States / cities
- Burlingame, California • La Jolla, California • Laguna Hills, California + 20 more
- Conditions
- Colorectal Cancer, Dermatologic Complications, Lung Cancer, Therapy-related Toxicity
- Interventions
- assessment of therapy complications, psychosocial assessment and care, quality-of-life assessment
- Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 113
- States / cities
- Tucson, Arizona • Castro Valley, California • Duarte, California + 78 more
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
- Interventions
- Bevacizumab, Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration, Topotecan Hydrochloride
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 541
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 351 more
- Conditions
- Traumatic Injury
- Interventions
- BE1116, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 1,366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 79 more
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Failed or Difficult Intubation, Sequela, Intubation;Difficult, Intubation Complication
- Interventions
- VL Coaching training using C-MAC video laryngoscope
- Device
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 22 Years to 70 Years
- Enrollment
- 1,512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 8
- States / cities
- La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 4 more
- Conditions
- Parkinson's Disease
- Interventions
- Mindfulness Based Stress Reduction, Psychoeducational Supportive Care
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 40 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- San Diego, California